Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. - Wikidata - awgldk - TriplyDB

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

http://www.wikidata.org/entity/Q34022444

about

Structural Basis of Regulation of von Willebrand Factor Binding to Glycoprotein Ib What have we learned from large population studies of von Willebrand disease?Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project.Critical von Willebrand factor A1 domain residues influence type VI collagen binding.Platelet GpIba binding to von Willebrand Factor under fluid shear:contributions of the D′D3-domain, A1-domain flanking peptide and O-linked glycans.von Willebrand factor, Jedi knight of the bloodstream Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.von Willebrand's disease: a report from a meeting in the Åland islands Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.Exploiting the kinetic interplay between GPIbα-VWF binding interfaces to regulate hemostasis and thrombosis The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.Diagnostic approach to von Willebrand disease Crucial role for the VWF A1 domain in binding to type IV collagen.Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.Gender, race and diet affect platelet function tests in normal subjects, contributing to a high rate of abnormal results.Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.Cloning of porcine platelet glycoprotein Ibα and comparison with the human homolog.New insights into genotype and phenotype of VWD.No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation Rapid discrimination of the phenotypic variants of von Willebrand disease.Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.Von Willebrand disease in the United States: a perspective from Wisconsin.Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.Collagen binding provides a sensitive screen for variant von Willebrand disease.von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein.Making a diagnosis of VWD.Pitfalls in special coagulation testing: three illustrative case studies.Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.Laboratory diagnosis of von Willebrand disease.Developments in the diagnostic procedures for von Willebrand disease.Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.A common VWF exon 28 haplotype in the Turkish population.Diagnostic challenges in patients with bleeding phenotype and von Willebrand exon 28 polymorphism p.D1472H.Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

P2860

Q27681197-02DF2FBA-763B-47CC-9334-7184426FE630 Q30240214-D2A54A51-B8B8-4C11-9235-7C9305F89E1A Q30411744-8157D643-EA63-40F2-9CA7-000AE20477B6 Q30555005-FD0974A9-3C1F-4475-BB83-555597D8554E Q30620128-9B7A83AA-2F07-4840-87F6-FF8952262ED8 Q34106824-9ACCA26A-128F-49E7-A6CA-C20C728FB444 Q34185963-EFDFD1B8-873B-441D-97AB-2A6A02AC7869 Q34223268-C1D7967D-3C47-4F56-8338-389A7FC59C1C Q34565109-BD190157-D4FF-47F5-9750-096908179571 Q34667787-540837C0-33C2-4611-A8B8-C2519C9740D5 Q34684020-3BC74ABA-E54F-4416-AA61-7E3B6438A464 Q34816051-CCF487A6-81BE-432E-84F8-C0EDDA00071E Q35220634-EF27A404-FA79-4A67-9DAF-8F81657D76FD Q35252688-1541B368-E000-4DD4-A644-CD9EE23DC27E Q35536246-4357DAB2-445D-4C89-8E1C-E0C3ACAFE0F9 Q35770815-0948A9E4-3DDB-45B0-A9AA-C1E5BFFE2DE3 Q35836882-B0955D6B-D4B7-438E-9A1F-691CD3030579 Q35849223-E0810CEF-4F83-46FD-BFD4-2E479566A480 Q36152568-88878427-AF3A-4527-9ACC-E9000F07A22F Q36417697-0B5C4ED7-14C9-4EE5-8C56-3372DC4836A6 Q36814657-88B845B2-E75E-4108-A54B-737F799C662B Q36920458-896DC617-5BB6-4D19-BA92-ED0CA681F130 Q36920462-60561D70-8B37-4C3F-A288-FACDAFAB4F5E Q36944971-707ECDE3-77F0-4716-B358-87E4EEA9BF3C Q37253917-622CBE53-D7A3-4868-BB6C-97DAE374D766 Q37259155-E3473E71-A3AA-4141-A63E-BA931E973221 Q37367262-C5B3D003-EBC0-4945-BE96-5AA8A3EC492D Q37635167-299F536D-66AF-4210-8342-9054FC7C18FF Q37703427-B0139A55-98D9-4A44-B988-CCB438392CFA Q37903943-0DEC675C-4CD0-4C65-86BB-D03BB3619CBA Q38066864-2CF736E9-B66C-4184-8ECD-663344B29E62 Q38088422-7A092E10-4C34-4B96-A1EC-EC7DCE261EA0 Q38205952-6E6EB6B2-BF71-465B-83D9-EC950BFC18CF Q38413638-7BFB5F7E-6BC6-4AB5-B3AE-AFC24E267121 Q38481908-12FAC73F-49AA-479A-83C7-D2340D197356 Q38682256-AF66AD51-52BD-4833-869B-058BB0062143 Q41174649-0EE168C0-D525-4EB9-98AD-EA4BE0424BC3 Q45050455-CEE0B527-1857-4348-A9B9-71F1CA4AFD31 Q45862885-73BAFA71-AB37-402C-808B-2FD32767E26C Q45868176-0677F48D-5230-492B-ABB6-244079F33F14

P2860

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

http://www.wikidata.org/entity/Q34022444

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@ast

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@en

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@nl

type

label

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@ast

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@en

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@nl

prefLabel

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@ast

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@en

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@nl

P1433

Q34022444-E9C6BEAC-0B7C-4BD0-BCDD-9866459F9F0D

P1476

Q34022444-1C8E6228-841C-461F-A2CA-1E6DEF861B9D

P2093

Q34022444-0399FA01-EA49-4DC8-89C5-A53636CD4916

Q34022444-07513D25-EDA1-4D97-98CB-1928512AE7DD

Q34022444-216A9BDE-EEFE-4514-8CC6-BCA566F395A2

Q34022444-291EE6ED-91B3-44B3-A6FC-459538FCF043

Q34022444-33F254DC-FB6E-4AD3-82A8-967BA6E519B4

Q34022444-36D351AA-A8BE-4383-B7E5-E37A1A3B65A1

Q34022444-5AC5B665-F40D-491B-8B34-6DAEC69A453E

Q34022444-677CDDC9-542E-4204-867B-9D1935BD2679

Q34022444-7B5ED5B3-8F3B-4914-94C7-138FCE730982

Q34022444-7D3E4256-D0B9-4FA5-B036-8D0A1CB76B75

P2860

Q34022444-0E2ADFC6-1B91-42F0-97A9-9F9E0AB9B3FF

Q34022444-15ABE5AC-AD91-4064-A018-A8DCD4AFF277

Q34022444-19ACA6F9-9FC7-43B3-B5FB-2BB08A48F3CD

Q34022444-291F3E9D-E9A8-44C3-BDCC-DF564445F533

Q34022444-3238D87B-BFC9-4760-B4FB-3D9B3F6E0B6E

Q34022444-45162FE6-B648-4E85-8E46-1FE81071D428

Q34022444-4F990B2C-8A0C-40D1-8A61-296D2A3A7AA8

Q34022444-65B6FB13-E2C8-4392-B532-EAB6428427D2

Q34022444-7D4208BD-8136-4D87-A035-7136681C74E9

Q34022444-8D03BC4E-BCAB-482C-A459-E2ACE05E13FE

P304

Q34022444-D48E51E1-5C64-4B83-8C33-559F4A285C53

P31

Q34022444-7C6031A5-C14E-4AB3-8ED6-993696D13791

P356

Q34022444-50FDB476-0F1A-4519-9A6D-62E71EF72830

P407

Q34022444-771DD914-ED22-4191-B0C4-13F8BF8FC72C

P433

Q34022444-62296259-9DDD-49E1-B8EF-8B59057F11C5

P478

Q34022444-9056C75C-F7E0-467D-810C-A6BAA3A73961

P577

Q34022444-1598F458-2A74-4FB4-B639-998521C64F02

P5875

Q34022444-E86E54E3-1138-4828-8ECD-88D4CF6CE5C1

P698

Q34022444-32F39A52-4737-4649-A44D-29202F13E22B

P932

Q34022444-E0AA1405-E3F2-4735-B84E-B44CFAD76B27

P356

BLOOD-2009-10-249102

P1433

P1476

Common VWF exon 28 polymorphis ...... assay by ristocetin cofactor.

@en

P2093

Amy D Shapiro

http://www.w3.org/2001/XMLSchema#string

Brian R Branchford

http://www.w3.org/2001/XMLSchema#string

Cindy Leissinger

http://www.w3.org/2001/XMLSchema#string

Jeanne M Lusher

http://www.w3.org/2001/XMLSchema#string

Joan Cox Gill

http://www.w3.org/2001/XMLSchema#string

Jorge A Di Paola

http://www.w3.org/2001/XMLSchema#string

Kenneth D Friedman

http://www.w3.org/2001/XMLSchema#string

Margaret V Ragni

http://www.w3.org/2001/XMLSchema#string

Pamela A Christopherson

http://www.w3.org/2001/XMLSchema#string

Patricia A Morateck

http://www.w3.org/2001/XMLSchema#string

P2860

Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain

The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha.

The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility.

von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

The effect of ABO blood group on the diagnosis of von Willebrand disease.

Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content

Hematologic complications arising during ristocetin therapy; relation between dose and toxicity.

The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Diagnosis of inherited von Willebrand disease: a clinical perspective.

P304

280-286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-10-249102

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41969073

http://www.w3.org/2001/XMLSchema#string

P698

20231421

http://www.w3.org/2001/XMLSchema#string

P932

2910611

http://www.w3.org/2001/XMLSchema#string